Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2024

The anti-vascular endothelial growth factor therapeutics market has grown marginally in recent years. It will grow from $12.18 billion in 2023 to $12.35 billion in 2024 at a compound annual growth rate (CAGR) of 1.3%. The growth observed during the historical period can be ascribed to several factors, including an increase in the prevalence of age-related macular degeneration, a heightened incidence of diabetic retinopathy, advancements in the diagnosis of retinal diseases, the clinical success and efficacy of treatments, and a notable shift towards outpatient treatment modalities. These factors collectively contributed to the expansion of the relevant market during the historical timeframe.

The anti-vascular endothelial growth factor therapeutics market is expected to see marginal growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The anticipated growth in the upcoming period is attributed to several key factors, including the aging population and the associated rise in ocular diseases, the broadening applications in addressing retinal disorders, the ongoing development of next-generation therapeutics, a growing emphasis on early intervention practices, global health initiatives promoting access to treatment, and increasing awareness. Major trends expected in the forecast period encompass the expanding utilization of anti-VEGF therapeutics in cancer treatment, a heightened focus on combination therapies within the field of ophthalmology, exploration of biosimilar versions for enhanced accessibility, ongoing research on resistance mechanisms, and the integration of these therapeutics with advanced imaging technologies. These trends are poised to shape and drive growth in the market, offering opportunities for innovation and advancement in healthcare.

The rise in the incidence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market. Ophthalmic disease prevalence signifies the occurrence of specific eye conditions or disorders within a given population. Anti-vascular endothelial growth factor (VEGF) therapeutics play a pivotal role in combating prevalent eye ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As of October 2022, the World Health Organization reported global vision impairment affecting approximately 2.2 billion people, with specific conditions impacting 1 billion individuals, including 8 million with age-related macular degeneration and approximately 3.9 million experiencing diabetic retinopathy. This prevalence underscores the driving force behind the growth of the anti-vascular endothelial growth factor therapeutics market.

The upsurge in healthcare infrastructure expenditure is poised to propel the expansion of the anti-vascular endothelial growth factor therapeutics market. Healthcare infrastructure expenditure represents the financial investment directed toward the development, maintenance, and enhancement of healthcare facilities and associated resources. Such expenditure plays a pivotal role in the anti-VEGF therapeutics market by bolstering treatment accessibility, encouraging technological advancements, raising awareness for early detection, and fostering collaborative efforts in research and development. As reported by the Office for National Statistics in May 2023, the UK witnessed a notable 9.4% increase in nominal healthcare spending and a corresponding 9.7% rise in real terms between 2020 and 2021. Additionally, preventive care spending surged to $45.72 billion in 2021, more than doubling from the previous year. Hence, the increased investment in healthcare infrastructure acts as a significant driver for the growth of the anti-vascular endothelial growth factor therapeutics market.

Advancements in therapeutic approaches represent a prominent trend driving growth within the anti-vascular endothelial growth factor therapeutics market. Companies active in this domain are embracing cutting-edge therapeutic methodologies to fortify their market presence. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based biopharmaceutical firm, disclosed phase 1 safety data for healthy subjects concerning their subcutaneous anti-VEGF wet AMD and DME candidates, namely D-4517.2 therapy. D-4517.2 is an innovative therapy designed to target unaddressed needs in DME conditions. Notably, this therapy is designed for self-administration through an autoinjector, allowing patients the convenience of self-administering the medication once monthly from the comfort of their homes.

Major players within the anti-vascular endothelial growth factor therapeutics sphere are strategically aligning through partnerships to propel the development and commercialization of VEGF inhibitors, thereby optimizing market gains. Such collaborations play a pivotal role in steering research and development, accessing novel technologies and candidates, expanding market penetration, and facilitating the commercial launch of VEGF inhibitors. For example, in June 2022, Biogen Inc., a US-based biotech enterprise, in collaboration with Samsung Bioepis, a South Korea-based biopharmaceutical company, introduced BYOOVIZ (ranibizumab-nuna) in the United States. BYOOVIZ stands as the premier FDA-endorsed ophthalmology biosimilar, specifically tailored for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Functioning as a vascular endothelial growth factor (VEGF) inhibitor, BYOOVIZ marks the inaugural biosimilar launch in the U.S. within the Biogen and Samsung Bioepis partnership. Under this collaboration, Samsung Bioepis is accountable for development, regulatory processes, and product manufacture, while Biogen shoulders the responsibility for commercialization.

In September 2021, AbbVie Inc., a prominent US pharmaceutical and innovation company, finalized a partnership agreement with Regenxbio Inc. for a substantial sum of $370 million. This strategic collaboration aims to leverage the collective expertise in eye care and gene therapy to advance the development of an anti-VEGF eye gene therapy. The joint effort involves the utilization of RGX-314 gene therapy, specifically designed to inhibit VEGF, addressing conditions such as wet age-related macular degeneration (AMD), retinal diseases, and diabetic retinopathy. Regenxbio Inc., a leading US biotechnology firm specializing in recombinant gene therapies, brings valuable capabilities to the collaboration.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market report are F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Applied Molecular Genetics Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2023. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-vascular endothelial growth factor therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products within the category of anti-vascular endothelial growth factor therapeutics include Eylea, Lucentis, and Beovu. Eylea is a medication specifically indicated for the treatment of certain eye conditions, such as macular degeneration and diabetic retinopathy. Serving as an anti-VEGF therapeutic agent, Eylea effectively hinders the abnormal growth of blood vessels in the eye, particularly associated with retinal diseases. The utilization of anti-vascular endothelial growth factor therapeutics extends to the treatment of macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. These therapeutics are commonly employed by hospitals, clinics, oncology centers, and other healthcare facilities in addressing a range of ophthalmic disorders.

The anti-vascular endothelial growth factor therapeutics market research report provides anti-vascular endothelial growth factor therapeutics market statistics, including anti-vascular endothelial growth factor therapeutics industry global market size, regional shares, competitors with a anti-vascular endothelial growth factor therapeutics market share, detailed anti-vascular endothelial growth factor therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. This anti-vascular endothelial growth factor therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.